Search Within

Dharmarao Thapi

Formats
  1. Meeting Abstract (31)
  2. Journal Article (7)
Groups
  1. Adult Leukemia (38)
  2. Center for Hematologic Malignancies (38)
  3. Gynecology Disease Management Team (9)
  4. Department of Medicine (7)
  5. GSK Faculty (7)
  6. Department of Pathology and Laboratory Medicine (6)

More Groups

People
  1. David Spriggs (31)
  2. Nestor Rosales (15)
  3. Xiu Yan (11)
  4. Xun Ma (7)
  5. Kay Park (6)
  6. John Diaz (5)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2018 (2)
  6. 2017 (1)

More Years

Publications
  1. Cancer Research (19)
  2. Clinical Cancer Research (4)
  3. Gynecologic Oncology (3)
  4. Journal of Clinical Oncology (2)
  5. ACS Chemical Biology (1)
  6. Applied Immunohistochemistry & Molecular Morphology (1)

More Publications

Publishers
  1. American Association for Cancer Research (24)
  2. Elsevier Inc. (4)
  3. American Society of Clinical Oncology (2)
  4. American Chemical Society (1)
  5. Elsevier Science Inc. (1)
  6. Frontiers Media S.A. (1)

More Publishers

Results (38)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MUC16 gene up-regulates gene transcripts associated with cisplatin resistance in human ovarian cancer cells
    Meeting Abstract

    Thapi, D.; Rosales, N.; Ma, X.; Kehoe, S. M.; Diaz, J. P.; Spriggs, D. R.
    Cancer Research (2007)

    Fulltext@MSK | Save
  • MUC16 gene expression inhuman oarian cncer cells and Cisplatin, resistance
    Meeting Abstract

    Thapi, D.; Kehoe, S. M.; Eisenhauer, E.; Boyd, J.; Dupont, J.; Spriggs, D. R.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • eEF1a2 overexpression has dual function in ovarian epithelial carcinoma
    Meeting Abstract

    Leiser, A. L.; Springett, G. M.; Rosales, N.; Thapi, D.; Spriggs, D. R.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Regulation of MUC16 (CA125) release in ovarian cancer cells by cytokines and growth factors
    Meeting Abstract

    Spriggs, E.; Spriggs, K.; Thapi, D.; Awtrey, C.; Spriggs, D. R.
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Induction of mitotic defect is a novel anti-tumor mechanism of histone deacetylase inhibitor suberoylanilide hydroxamic acid
    Meeting Abstract

    Xu, W.; Perez, G.; Gui, C.; Thapi, D.; Ngo, L.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitor activation of p21 involves changes in promoter associated proteins, including HDAC1
    Meeting Abstract

    Gui, C.; Ngo, L.; Xu, W.; Thapi, D.; Perez, G. V.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Phase I clinical trial of an oral histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W. K.; O'connor, O.; Richon, V. M.; Curley, T.; Richardson, S.; Thapi, D.; Chiao, J. H.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W.; O'connor, O.; Richon, V. M.; Tong, W.; Rao, T. D.; Chiao, J.; O'Brien, J. P.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save